NCT06947395View on ClinicalTrials.gov

Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)

CompletedOBSERVATIONAL
Enrollment

386

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

March 24, 2025

Study Completion Date

April 7, 2025

Conditions
Cancer of the PancreasPancreatic CancerPancreas NeoplasmsPancreatic Carcinoma Stage IPancreatic Carcinoma Stage II
Interventions
DIAGNOSTIC_TEST

PancreaSure

Serum-based biomarker test comprised of ELISA-based analyte readings of 4 protein biomarkers (ICAM-1, TIMP1, THSB1, and CTSD) and CA19-9 summed by a mathematical algorithm with associated coefficients where a pre-defined cutoff establishes a positive or negative detection of PDAC.

Trial Locations (6)

10016

New York University Langone Health, New York

23284

Virginia Commonwealth University, Richmond

38103

Regional One Health, Memphis

75235

UT Southwestern Medical Center, Dallas

85258

HonorHealth Clinical Research Institute, Scottsdale

15213-2582

University of Pittsburgh Medical Center, Pittsburgh

Sponsors

Lead Sponsor

Immunovia, Inc.
All Listed Sponsors
lead

Immunovia, Inc.

INDUSTRY

NCT06947395 - Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI) | Biotech Hunter | Biotech Hunter